Primary Job Title Chairman and CEO Primary Organization 
Bloodstone Ventures
Gender Male
Dr. Nash brings to Accera more than 20 years of executive management experience in the pharmaceutical and biotechnology industries.
Claude Nash is currently the chairman and CEO of Bloodstone Ventures plc.
Previously he was the founder, CEO, and chairman of ViroPharma Inc. where he oversaw the development of several antiviral drugs,
successfully raised $430M in capital and achieved a $1.2B market capitalization for the company following its Initial Public Offering.
Prior to founding ViroPharma, Dr. Nash was Vice President of infectious disease and cancer research at the Schering-Plough Research Institute where he initiated new strategic technologies for drug discovery and advanced three new drugs into development. Throughout his career he has managed the research and development of more than twenty drugs in the areas of infectious diseases, cancer, hypertension and pain.
In the past he worked for several large pharmaceutical companies including Sterling-Winthrop, Smith Kline & French, and Eli Lilly. He is currently a director of Adolor, Inc.
Dr. Nash earned his Ph.D. degree in microbial genetics and biochemistry from Colorado State University.
